| Assessment Status | Rapid review complete |
| HTA ID | - |
| Drug | Sofosbuvir/velpatasvir |
| Brand | Epclusa® |
| Indication | For the treatment of chronic hepatitis C virus (HCV) infection in adults. This indication covers all genotypes (GT1, 2, 3, 4, 5 and 6) i.e. pangenotypic. |
| Assessment Process | |
| Rapid review commissioned | 05/09/2017 |
| Rapid review completed | 19/10/2017 |
| Rapid review outcome | Full pharmacoeconomic assessment not recommended |